The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation by Lion, T et al.
ORIGINAL ARTICLE
The EuroChimerism concept for a standardized approach to
chimerism analysis after allogeneic stem cell transplantation
T Lion1, F Watzinger1, S Preuner1, H Kreyenberg2, M Tilanus3, R de Weger4, J van Loon4, L de Vries4, H Cave´5, C Acquaviva5, M Lawler6,
M Crampe6, A Serra7, B Saglio7, F Colnaghi8, A Biondi8, JJM van Dongen9, M van der Burg9, M Gonzalez10, M Alcoceba10, G Barbany11,
M Hermanson11, E Roosnek12, C Steward13, J Harvey14, F Frommlet15 and P Bader2 on behalf of the EuroChimerism Consortium
(EU-Project number: QLG1-CT-2002-01485)
Hematopoietic stem cell transplantation is becoming an increasingly important approach to treatment of different malignant
and non-malignant disorders. There is thus growing demand for diagnostic assays permitting the surveillance of donor/
recipient chimerism posttransplant. Current techniques are heterogeneous, rendering uniform evaluation and comparison of
diagnostic results between centers difficult. Leading laboratories from 10 European countries have therefore performed a
collaborative study supported by a European grant, the EuroChimerism Concerted Action, with the aim to develop a
standardized diagnostic methodology for the detection and monitoring of chimerism in patients undergoing allogeneic stem
cell transplantation. Following extensive analysis of a large set of microsatellite/short tandem repeat (STR) loci, the
EuroChimerism (EUC) panel comprising 13 STR markers was established with the aim to optimally meet the specific
requirements of quantitative chimerism analysis. Based on highly stringent selection criteria, the EUC panel provides multiple
informative markers in any transplant setting. The standardized STR-PCR tests permit detection of donor- or recipient-derived
cells at a sensitivity ranging between 0.8 and 1.6%. Moreover, the EUC assay facilitates accurate and reproducible quantification
of donor and recipient hematopoietic cells. Wide use of the European-harmonized protocol for chimerism analysis presented
will provide a basis for optimal diagnostic support and timely treatment decisions.
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INTRODUCTION
Quantitative monitoring of recipient- and donor-derived cells by
molecular methods has become an indispensable diagnostic tool
in the surveillance of patients undergoing allogeneic hemato-
poietic stem cell transplantation. The analysis of patient/donor
cell chimerism during the posttransplant period reveals immuno-
logical interactions between donor and recipient providing important
information for preemptive therapeutic interventions. In addition
to facilitating the assessment of successful engraftment, monitor-
ing of chimerism at regular intervals can provide an early
indication of imminent graft rejection1 -- 3 and, in patients with
malignant hematological disorders, a timely alert of impending
relapse.4 -- 8 The number of allogeneic stem cell transplants
performed worldwide has been steadily growing over the past
years. In particular, the increasing employment of reduced
intensity conditioning regimens and cord blood transplants,
which require very careful surveillance of the graft, has
contributed to the clinical importance of chimerism testing. In
contrast to fluorescence in situ hybridization, short tandem repeat
(STR)-PCR can be applied to routine diagnostic monitoring of
chimerism in any transplant setting. However, the heterogeneity
of technical approaches to chimerism analysis and the diversity
of STR markers used have compromised the comparison of
results generated at different centers. The EuroChimerism (EUC)
consortium (including 12 centers from 10 European countries;
Table 1) has been constituted to address the urgent need for a
standardized technology specifically adapted to the requirements
of quantitative chimerism analysis. The paramount goal of the
ensuing collaborative study termed EuroChimerism Concerted
Action was to establish a standardized approach to quantitative
chimerism testing with the aim to facilitate harmonization of
chimerism diagnostics between European centers, and to provide
a basis for appropriate quality control.
A variety of technical approaches to chimerism analysis are
currently used. Techniques based on PCR amplification of
polymorphic DNA sequences, facilitating unequivocal distinction
and quantitative assessment of recipient- and donor-derived cells,
have been the preferred approach to chimerism testing at most
centers. Despite the potential of single nucleotide and insertion/
deletion polymorphism analysis by real-time PCR,4,9 -- 16 the
investigation of microsatellite (STR) polymorphisms is currently
the most widely used technique in clinical chimerism testing.
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The methods of STR-PCR analysis performed in different diagnostic
laboratories are usually based on rather diverse in-house assays,
although attempts to introduce a commercially available platform
for chimerism testing (http://www.biotype.de) or to exploit
existing microsatellite kits designed for forensic purposes have
been made. The EUC consortium has therefore established the
basis for a diagnostic kit based on STR-PCR analysis, designed to
optimally meet the requirements of clinical chimerism testing.
The EuroChimerism Concerted Action was supported by a grant
from the European Commission (within the fifth Framework
program) and included five work packages covering the most
important aspects of chimerism analysis (Supplementary Table SI-1).
In this report, we present the results of the EuroChimerism
Concerted Action with the intention to provide an impetus for
laboratories involved in chimerism testing to join this European
initiative aiming at the establishment of widely accepted
diagnostic standards. Based on the collaboration of the EUC
consortium with an industrial partner (Miltenyi Biotech, Bergisch
Gladbach, Germany) a multiplex PCR kit for the identification of
informative STR markers (ChimerXplain, Bergisch-Gladbach, Ger-
many) and a singleplex PCR kit specifically adapted for
quantitative chimerism analysis (ChimerXact, Bergisch-Gladbach,
Germany) will soon be commercially available, and may serve as a
tool for the harmonization of posttransplant monitoring between
diagnostic laboratories.
MATERIALS AND METHODS
Details of various methodological procedures are presented online as
Supplementary Information, including the approaches to DNA isolation
and appropriate controls,17 PCR amplification of singleplex and multiplex
reactions (Tables 2 and 3), capillary electrophoresis of amplicons, relevant
definitions,18 and detailed information on statistical analysis. Efficient
approaches to DNA isolation for chimerism testing have been specifically
addressed in a recent publication of the EUC consortium.17
Preparation of dilution series
As outlined in more detail in the statistics section (Supplementary
Information), important parameters of chimerism analysis, including
the detection limit (DL), reproducibility and accuracy were assessed by
testing centrally prepared serial dilutions of recipient DNA in donor DNA
mimicking different levels of mixed chimerism. Combinations of DNA
samples providing informative allelic constellations were selected to
prepare four different dilution series including the following steps: 50, 25,
12.5, 6, 3, 1.6 and 0.8%. In addition to the initial DNA measurement by
optical density, the presence of identical concentrations of DNA in all steps
of the dilution series was controlled by real-time PCR amplification of
albumin as control gene.19
Quantitative analysis of chimerism status
Based on measurements of the donor/recipient peak height ratios,
chimerism levels were calculated using formulas specifically adapted for
different allelic constellations (Table 4).
Transfer of materials
At several stages of the study, different control materials including primers,
DNA preparations and PCR products were centrally prepared and
distributed either to a restricted number of laboratories or to all
participating centers. In the present study, archived materials from
Table 1. EuroChimerism consortium
Austria
Children’s Cancer Research Institute, Vienna
Thomas Lion (Coordinator)
Franz Watzinger
Sandra Preuner
Department of Medical Statistics, CEMSIIS, Medical University Vienna
Florian Frommlet
Germany
Department of Pediatrics, University Frankfurt
Peter Bader (Deputy coordinator)
Hermann Kreyenberg
Italy
Department of Pediatrics, University Milano, Monza
Andrea Biondi
Federica Colnaghi
Department of Clinical and Biological Sciences, University Turin
Anna Serra
Giuseppe Saglio
Spain
Department of Hematology, University Salamanca
Marcos Gonza´lez-Dı´az
Miguel Alcoceba
Switzerland
Department of Hematology, University Geneva
Eddy Roosnek
Solange Vischer
France
Hopital Robert Debre´, Paris
He´le`ne Cave´
Ce´cile Acquaviva
Ireland
St. James Hospital, Dublin
Mark Lawler
Mireille Crampe
Karen Molloy
The Netherlands
Department of Transplantation Immunology Maastricht University
Medical Center
Marcel Tilanus
Department of Pathology, University Medical Center, Utrecht
Roel de Weger
Joyce van Loon
Department of Immunology, Erasmus University Rotterdam
Jacques J.M van Dongen
Mirjam van der Burg
Sweden
Clinical Genetics, University Hospital, Uppsala
Gisela Barbany
Monica Hermanson
United Kingdom
Royal Hospital for Children, Bristol
Colin Steward
H&I Laboratory, National Blood and Transplant Service, Bristol
John Harvey
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patients who had given their consent to chimerism analysis before
transplantation were used. Shipment was performed at ambient tempera-
ture by an overnight express service.
Statistical analysis
Definition of variables. To investigate the performance of the 13 markers
of the EUC panel with regard to the DL and the accuracy of quantitative
assessment of donor/recipient cell ratios, four dilution series including the
dilution steps indicated above were generated. Based on the definitions of
allelic constellations eligible for chimerism testing using the RSD code
established by the EUC consortium,18 a total of 36 informative marker
constellations (IMCs) were available for investigation. The analysis was
designed to address the question to which extent individual factors
including the specific center involved, the dilution series used, the STR
marker investigated and certain aspects of the IMC indicated below might
have an influence on the two dependent variables-DL and divergence
(accuracy).
The chimerism levels for different recipient and donor allele constella-
tions, as specified by the RSD code,18 were calculated according to the
formulas indicated in Table 4 based on the respective donor and recipient
peak heights. For IMCs potentially compromised by stutter peak formation,
modified formulas were used in which the peak affected by the stutter was
substituted by doubling the peak height of the unaffected recipient peak
(Table 4).
Study design. The parameters including DL, reproducibility, divergence
(accuracy) and linearity were determined by testing the dilution series of
Table 2. EUC markers, primer sequences, fluorescence labels and
primer concentrations in singleplex reactions
Marker Sequence (50 -- 30) Fluorescence
label
Primer conc.
(nM) for
singleplex
reactions
D2S1360
Fw CTGCATTAAAACATTCGAAACCAA JOE 80
Rev GCAGCAGATTGTGGGACTTCTCAG 80
D7S1517
Fw AGCCTGATCATTACCAGGT JOE 160
Rev GTTTCTATTGGGGCCATCTTGC 160
D8S1132
Fw TCTCTCTCTCCCTCTCTCTTTCGAG TMR 80
Rev GTTTGCCATCTTCTTACCTCTGTTGGTC 80
D9S1118
Fw CAGGATATTATGTGATGGAATCC FL 320
Rev GATCTCTTCTCTCTCTCTCTTTCTCCC 80
D10S2325
Fw TATGGTGACCTTAAGCAGCCATG JOE 80
Rev GTGTCTTAGCTGAGAGATCACGCACTGC 80
D11S554
Fw GGTAGCAGAGCAAGACTGTC FL 80
Rev GTTTCACCTTCATCCTAAGGCAGC 80
D12S1064
Fw ACTACTCCAAGGTTCCAGCC TMR 160
Rev ACTGTTATCTCTCTTGTGGTAG 160
D12S391
Fw ATCAACAGGATCAATGGATGCAT FL 160
Rev GGGCTTTTAGACCTGGACTGAG 160
D17S1290
Fw CCAACAGAGCAAGACTGTC FL 80
Rev GTTTGAAACAGTTAAATGGCCAAAG 80
D19S253
Fw ATAGACAGACAGACGGACTG FL 160
Rev GTTTGGGAGTGGAGATTACCCCT 160
MYCL1
Fw AACCGTAGCCTGGCGAGACT FL 160
Rev GTTTCCTTTTAAGCTGCAACAAATTTC 160
P450CYP19
Fw GTTCCACATAATGAAGCACAATC FL 240
Rev GTTTAATCGCCTGAGTCCTGGGA 240
SE-33
Fw AATCTGGGCGACAAGAGTGA FL 160
Rev ACATCTCCCCTACCGCTATA 160
Abbreviations: EUC, EuroChimerism; Fw, forward; Rw, reverse. The
acronyms JOE, TMR, and FL designate green, yellow, and blue fluorescence
dyes, respectively.
Table 3. EUC multiplex panels
Primer
concentrations
(nM)
FL JOE TMR
Group 1
D9S1118 a 92--128
MYCL1 240 156--225
D7S1517 200 164 --212
D11S554 400 166 --246
D8S1132 400 347 --379
Group 2
D10S2325 360 163--213
D12S391 480 237--269
P450CYP19 800 314--464
D2S1360 800 233 --273
Abbreviation: EUC, EuroChimerism. The acronyms JOE, TMR, and FL
designate green, yellow, and blue fluorescence dyes, respectively.
aD9S1118 asymmetric PCR: fw primer 640 nM and rev primer 160 nM. The
range of allele sizes is indicated.
Table 4. Formulas for calculation of recipient chimerism levels for
different recipient and donor allele constellations
Allele constellations Recipient chimerism level (%)
RD, DR HR/(HR+HD)
RRD, RDR, DRR (HR1+HR2)/(HR1+HR2+HD)
RDD, DRD, DDR HR/(HR+HD1+HD2)
RRDD, DDRR,
DRRD, RDDR,
RDRD, DRDR
(HR1+HR2)/(HR1+HR2+HD1+HD2)
RSD, DSR,
SRD, SDR HR/(HR+HD)
rDR, 2*HR2/(2*HR2+HD)
RrD 2*HR1/(2*HR1+HD)
RdrD HR1/(HR1+HD2)
rdRD HR2/(HR2+HD2)
RrDD 2*HR1/(2*HR2+HD1+HD2)
rDRD 2*HR2/(2*HR2+HD1+HD2)
The indicated examples of allele constellations are based on the RSD code
(see Supplementary Figure 1). The formulas for calculation of chimerism
levels are based on peak heights (H) of the recipient allele(s) (HR, HR1, HR2)
and the donor allele(s) (HD, HD1, HD2), respectively. The subscripts indicate
the shorter (1) and the longer (2) recipient (R)/donor (D) alleles, as present in
the respective constellation. Alleles potentially affected by stutter peak
formation
(lower case letters) are disregarded in the formulas for the calculation
of chimerism, and are substituted by doubling the peak height of the
unaffected allele.
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recipient in donor DNA described above according to an incomplete
balanced block design (Supplementary Information).20
Statistical methods. To analyze the influence of the factors center,
dilution series and allelic imbalance on the DL, proportional odds models21
using PROC LOGISTICS of SAS (SAS Institute Inc., 2000, Cary, NC, USA) were
applied. The effects on accuracy of the random factors center, dilution
series, marker, IMC, the fixed factors dilution step and the covariate allelic
imbalance were investigated by a mixed model analysis using PROC MIXED
of SAS22 on the basis of reproducible data obtained from the participating
centers (Supplementary Information).
RESULTS
Cell number and DNA template requirements for quantitative
chimerism analysis
In comparison to the commonly performed chimerism testing
within total white blood cells, assessment of chimerism within
specific leukocyte fractions may provide earlier and more specific
information on impending complications in various instances.1,4,23
When rare cell subsets are isolated for subsequent chimerism
analysis, the availability of sufficient amounts of DNA may become
a limiting factor with regard to the achievable sensitivity and
reproducibility of results. The experience among members of the
EUC consortium indicated that the cell number available for
analysis in these instances can be as low as a few hundred to a
few thousand cells. Based on the DNA content of human
nucleated cells and the efficiency of nucleic acid extraction, the
amount of DNA available as template for subsequent chimerism
analysis by PCR can therefore be as low as 1--10 ng. Based on this
notion, we performed a series of experiments addressing the DL
and the reproducibility of chimerism testing in samples containing
1 and 10 ng DNA template. Multiple dilution series representative
of different clinical posttransplant specimens were tested in
duplicate assays, focusing particularly on the analysis of samples
containing 1 and 10 ng of total DNA template. The results
indicated that DLs of 0.8 --1.6% are achievable with either
template amount in about 90% of instances. However, the
reproducibility, defined as the concordance between replicate
tests, was clearly superior in specimens containing 10 ng DNA
template: the maximum differences observed in X90% of
replicate measurements were ±1% for the lowest dilutions
containing 0.8 --1.6% of donor or recipient DNA. These observa-
tions indicated that STR-PCR reactions containing 10 ng of
template nucleic acid, corresponding to the DNA content of
B1.500 human diploid cells, can be regarded as the minimum
requirement for reproducible chimerism testing with adequate
DLs. Based on these findings, all subsequent experiments were
carried out using 10 ng of DNA per PCR reaction.
Establishment of the EUC STR marker panel
The EUC consortium has addressed the principles of marker
eligibility for chimerism testing in a separate article in which the
effect of allelic constellations on quantitative analysis is discussed,
and the criteria for the selection of adequate microsatellite
markers are presented.18 The most important properties of eligible
markers are outlined in the Supplementary Information.
The selection process of microsatellite loci optimally suited for
quantitative chimerism testing was started by compiling the best
performing markers from individual participating centers. This
initial collection of markers, which is displayed in Table 5, was
based on long-lasting experience with microsatellite analysis in
the surveillance of chimerism in leading European laboratories.
The main criteria for the compilation of the initial panel included
the informativeness (see definitions in the Supplementary
Information) and the DLs of individual markers observed in
routine clinical diagnosis. As a first step of evaluation by the EUC,
each of the markers from the initial panel was tested at different
centers for its informativeness in a minimum of 50 related donor/
recipient pairs (as related individuals display a particularly high
probability of shared alleles). The best performing markers were
selected for further testing, as described below and finally resulted
in the establishment of the EUC STR marker panel (Table 2).
Detailed analyses and allele frequencies of the 13 selected EUC
STR markers are presented in Supplementary Tables SI-2a and b.
Most of the markers display four-nucleotide repeat motifs, but
some contain combinations of different tetranucleotide repeat
sequences.24 The predominant variable repeats are indicated in
Table 5, and details of the complex repeats were described
earlier.24 Upon establishment of the EUC marker panel, a variety of
different primers, combinations and concentrations were tested
for each individual marker. The criteria of eligibility included (a)
reproducible achievement of peak heightsX6.000 RFU with 10 ng
DNA template, (b) secondary stutter peaks o1% of main peaks
and (c) absent or low background noise (o50 RFU). The selected
primers and combinations were optimized for quantitative
analysis of chimerism under uniform amplification conditions
(Supplementary information).
Informativeness of the EUC STR marker panel
The informativeness of individual microsatellite loci was deter-
mined by testing their ability to provide allelic constellations
eligible for quantitative chimerism analysis according to the
guidelines of the EUC.18 Briefly, the minimum requirements for an
eligible allelic constellation include the presence of at least one
unique donor and recipient allele and a distance between
informative alleles corresponding to at least two tandem repeat
units. The informativeness of markers included in the initial panel
was determined under stringent conditions reflecting the most
challenging situation, which is the related transplant setting.
In total, 740 related and 159 unrelated donor/recipient pairs were
tested by the EUC marker panel. EUC markers were ranked
according to the previously defined criteria.18 For all markers,
the heterozygosity index, the polymorphism information content
(PIC value)25 and the combined probability were calculated (Table 6).
The informativeness of the EUC panel was compared with that
of a commercial multiplex microsatellite marker kit designed for
forensic analysis (Powerplex16, Promega, Mannheim, Germany).
Table 5. Primary panel of STR markers investigated
Name Repeat Motif
D12S391 Tetra [GATA]n [GACA]n
D20S194 Di [CA]n
D12S1064 Tetra [TATC]n
D17S1290 complex [TGA]n[TAGA]n
D13S317 Tetra [TATC]n
CSF1PO Tetra [AGAT]n
MYCL1 complexa [GAAA]n[GAAAA]n
P-450 Cyp19 Tetra/Penta [TATTT]n[TATT]n
vWF II Tetra [TCTA]n
D3S1768 Tetra [TAGA]n
D9S1118 Tetra [TATC]n
D11S554 complex [AG]n [AAAG]n
D19S253 Tetra [ATAG]n
D7S1517 Tetra [GAAA]n[CAAA]n
D10S2325 Penta [TCTTA]n
D2S1360 Tetra [TAGA]n[CAGA]n
D8S1132 Tetra [CTAT]n
SE33 complex [AAAG]n
a
The predominant repeat motifs of the complex repeat markers are
indicated. The most variable motifs of the tetranucleotide repeats are
indicated. Details of the repeat content has been described elsewhere.22
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The kit, which includes 16 microsatellite loci, was tested in 320
related donor/recipient pairs and revealed a level of informative-
ness inferior to the EUC panel, with regard to the specific needs of
chimerism analysis.
The standards established by the EUC consortium requesting
the availability of at least two bidirectionally informative micro-
satellite markers for chimerism testing in any patient/donor
constellation was met by the EUC panel. Combined analysis of the
five most informative STR markers including SE33, D11S554,
D9S1118, D7S1517 and D2S1360 revealed a 499% probability of
finding bidirectionally informative allelic constellations, a level that
could not be achieved with the Powerplex16 kit. The EUC panel
revealed multiple markers eligible for chimerism testing in
virtually all instances, even under the stringent conditions of the
related donor/recipient setting. The high level of informativeness
for chimerism testing provided by the loci included in the EUC
panel is documented by the allele frequencies of individual
markers (Supplementary Tables SI-2a and b).
Multiplexing of EUC markers
The monitoring of chimerism by STR-PCR is most commonly
performed by assays based on the amplification of a single
microsatellite marker per reaction, because singleplex PCR assays
generally provide the highest achievable level of sensitivity. For the
initial selection of one or more eligible markers, however, it is
advantageous to employ a multiplex test facilitating simultaneous
testing of multiple microsatellite loci. Markers that can be tested in
a multiplex reaction either must have a non-overlapping spectrum
of allele sizes or the PCR products of each marker must be labelled
differentially to permit clear assignment of the amplification
products by fluorescence-based electrophoresis. A number of
fluorescent dyes are available for the labelling of amplification
primers, thereby permitting coamplification of multiple micro-
satellite targets. There are, nevertheless, limitations with regard to
the number and type of microsatellite loci that can be compiled in
a multiplex PCR reaction. Owing to the high level of informative-
ness of the markers included in the EUC panel, only a limited
number of loci need to be tested in a multiplex assay to identify
more than one marker eligible for quantitative monitoring of
chimerism in any donor/recipient constellation. It appeared
reasonable therefore to establish multiplex assays targeting a
restricted number of microsatellite loci. Based on the number of
currently available dyes and the allelic spectra of the EUC markers,
two multiplex assays, one pentaplex and one tetraplex, were
established. The loci included in the multiplex reactions and the
respective primer concentrations are indicated in Table 3. The
probability of identifying more than one informative marker in any
given donor/recipient pair was calculated for both multiplex
reactions on the basis of allelic frequencies in the European
population covering patients with diverse ethnic backgrounds:
under the stringent criteria of eligibility, the probability is 84.5%
for the pentaplex assay, 57.6% for the tetraplex assay and 97.7%
for both assays combined. These numbers indicate that initial
screening by the pentaplex assay alone will be sufficient to
provide at least two eligible markers for posttransplant chimerism
testing in most instances. Concomitant employment of both
multiplex assays, or implementation of additional markers from
the EUC panel currently not included in any of the multiplex
reactions, will only be required in rare instances. It is conceivable,
however, that the current multiplex assays will be further
optimized by the manufacturer of the diagnostic kit (Miltenyi
Biotec; see below).
DL of the EUC markers
Statistical analysis of DLs (i.e., sensitivity) and other validation
parameters of the EUC panel were based on an incomplete
balanced block design (see Materials and Methods, statistical
analysis-Supplementary Information). The DL for the 13 markers
of the EUC panel was between 0.8 and 1.6% in the great majority
of the samples analyzed. The lowest limit of detection tested
(0.8%) was reached in 66% of all analyses, whereas 22.3% of
the tests had a DL between 0.8 and 1.6%, and 10.4% of tests
between 1.6 and 3%. In three instances only (1.4%), the DL
achieved was between 3 and 6%. At first sight, it appeared
intriguing that the analysis of three STR markers (D17S1290,
D12S1064 and D19S25) revealed a DL of 0.8% in all experi-
ments performed. This observation, however, was shown to be
attributable to particular allelic constellations rather than to the
markers themselves. Analysis of the DLs in relation to the allelic
constellation revealed that in cases displaying homozygous
recipient and heterozygous donor alleles, a DL of 0.8% for
recipient cells was reached in most instances (93%), and a limit
of 1.6% in the remaining tests. By contrast, the few analyses
displaying a DL for recipient cells of X3% had the opposite
allelic constellation (recipient heterozygous/donor homozygous).
Our observations indicate that this constellation tends to
reveal lower recipient peaks, which sometimes remain below
the minimum requirement of unequivocally detectable signals
(o50 RFU) even at recipient chimerism levels X3%, despite the
employment of optimized detection parameters. In contrast to
the allelic constellation, logistic regression analysis of other factors
including allelic imbalance, dilution series or center revealed no
influence on the achievable DLs.
Reproducibility and accuracy of quantitative analysis
Analysis of the factors reproducibility and accuracy was also based
on the incomplete balanced block design. The concordance
between replicate singleplex assays based on the analysis of 10 ng
of template DNA revealed a maximum intrinsic variability of±1%
and ±2--3% for samples with low (p1.6%) and higher propor-
tions (43%) of recipient cells, respectively. The parameter
accuracy, which displayed a somewhat higher degree of intrinsic
variability, was therefore identified as a more relevant determinant
Table 6. Informativeness of the STR markers
EUC markers
Name HI PIC value EUC criteria Combined probability
SE33 0.9412 0.9380 0.8277 0.8277
D11S554 0.9424 0.9396 0.7115 0.9503
D9S1118 0.8412 0.8221 0.5447 0.9774
D7S1517 0.8630 0.8492 0.4945 0.9886
D2S1360 0.8459 0.8324 0.4915 0.9942
D10S2325 0.8728 0.8595 0.4782 0.9970
MYCL-1 0.9282 0.9242 0.4614 0.9984
D12S391 0.8748 0.8629 0.4583 0.9991
D17S1290 0.8459 0.8282 0.4059 0.9995
D8S1132 0.8641 0.8487 0.3959 0.9997
D19S253 0.7982 0.7687 0.3706 0.9998
D12S1064 0.8485 0.8307 0.3331 0.9999
P450-CYP19 0.7649 0.7252 0.2850 0.9999
The Heterozygosity Index (HI) and Polymorphic information content (PIC)
values were calculated from the allele frequencies for each EUC-STR
(EuroChimerism-short tandem repeat) marker. The frequencies considering
the EUC criteria reflect the informativeness based on the likelihood to
identify patient- and donor-specific allele(s) separated by at least two
repeat lengths (to prevent any influence of stuttering on the peak height).
The combined probability (CP) indicates the increasing chance of finding
informative markers by testing additional microsatellites. Under the
stringent EUC criteria, analysis of five EUC markers provides a 99% chance
of finding one or more informative markers in any patient/donor
constellation.
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for quantitative analysis of chimerism and the establishment of
appropriate confidence intervals. The raw data reflecting the
accuracy of measurements, assessed by the disparity between the
actual recipient/donor ratio in defined cell mixtures and the
experimentally determined values of chimerism (Figure 1),
indicated the greatest deviations of up to±5% in 50/50 mixtures
of recipient in donor DNA. Deviations from ideal values observed
in mixtures containing lower proportions of recipient DNA
(25--12.5%) were less pronounced, as shown in Figure 1. Mixtures
containing percentages of recipient DNA ranging between 0.8 and
6% showed a very similar pattern of divergence from the ideal
values, with a tendency to overestimate the level of chimerism by
up to about 2% (Figure 1).
Impact of allelic constellation and unbalanced amplification on
quantitative analysis
The divergence between the true and the experimentally
determined chimerism levels was assessed by testing well-defined
serial dilutions of recipient in donor DNA according to the mixed
model analysis described in the statistical methods section.
Although certain variables including the individual centers and
dilution series showed no significant effect of the divergence, a
differential influence of the microsatellite marker used was
observed. Detailed analysis revealed, however, that the effect on
divergence was not attributable to the marker itself (P¼ 0.35), but
rather to the specific allelic constellation (IMC; P¼ 0.006), which
was an important variable (random factor) in the final mixed
model analysis.
Moreover, the factor allelic imbalance was identified as an
important variable significantly affecting the accuracy of quanti-
tative analysis of chimerism (P¼ 0.02): in principle, longer DNA
fragments tend to be amplified less efficiently by PCR. Although
the difference in size between sister alleles of judiciously selected
STR markers is generally small, preferential amplification of shorter
alleles leading to higher peaks has been observed in heterozygous
constellations. This phenomenon, referred to as allelic imbalance,
did not show any influence on the DL, but can affect quantitative
analysis of STR-PCR assays in terms of accuracy. For markers of the
EUC panel, the maximum bias attributable to this phenomenon, in
the range of ±2%, was observed in the presence of large
distances between informative donor and recipient alleles
(440 bp), and mixed chimerism levels at 50%. The maximum
bias was less pronounced at all other levels of mixed chimerism.
For levels of donor or recipient chimerism below 6%, the
maximum bias conferred by allelic imbalance was only in the
range of ±0.25%. The experience of the EUC consortium
indicated that the occurrence of unbalanced allele amplification
was largely attributable to suboptimal set-up of PCR assays. The
factors influencing the balance between amplification efficiencies
of STR sister alleles were shown to include primarily the amount of
DNA template and the total number of PCR cycles performed. As
sister alleles do not have the properties of perfect competitors in
the reaction, imbalances may occur particularly if the PCR is
performed beyond the exponential phase of amplification. In the
presence of 10 ng of template DNA, which was the standard
amount in all singleplex assays using the EUC marker panel,
amplification under the conditions indicated in Materials and
Methods was shown to prevent relevant inaccuracies of quanti-
tative analysis in heterozygous allelic constellations.
Approach to calculation of recipient/donor chimerism
The heights and peak areas of fluorescence signals provided by
capillary electrophoresis were evaluated by analyzing a large
series of PCR amplification products generated by EUC STR
markers. Quantitative assessment of chimerism based on either
heights or areas of individual peaks yielded comparable results. In
view of the more convenient determination, peak heights were
used for all subsequent analyses of chimerism throughout the
study. Based on the background noise, the lower threshold for
signals that can be regarded as positive was set at 50 RFU. For
quantitative analysis of minor signals, the peak heights of
dominant alleles must not be off-scale (the maximal legitimate
height depends on the instrument used). Conversely, the peaks
must display a defined minimal height (minimal threshold of peak
heights; MTPH) in order to permit the detection of minor signals
with adequate sensitivity, as outlined in the Materials and
Methods section. The above prerequisites for the calculation of
chimerism were achieved by appropriate adjustment of analysis
parameters for capillary electrophoresis including the injection
time and voltage, and if required, the amount of PCR product
analyzed. When the indicated criteria for quantitative analysis
were met, calculation of the chimerism levels was performed by
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Figure 1. EUC markers---accuracy of quantitative assessment. The
raw data of the assessment of accuracy indicated by the divergence
(in percent; y axis) between measured (individual dots) and true
values (¼dilution steps; x axis) are displayed for the analyses per-
formed.
Table 7. Confidence intervals of accuracy defined for recipient
chimerism results
Percentage recipient
chimerism Posttransplant monitoring
By a single
STR marker
By two or more
STR markers
CI (95%) CI (99% ) CI (95%) CI (99%)
o 6% or 494% m±1.6 m±2.1 m±1.8 m±2.4
6 --12% or 87--94% m±2.8 m±3.7 m±3.3 m±4.3
12--25% or 75--87% m±3.0 m±4.0 m±4.3 m±5.7
25--75% m±3.8 m±5.0 m±5.7 m±7.5
The pointwise two-sided confidence intervals (CI) are based on a mixed-
effects model including the random factor IMC (informative marker
constellation), and the fixed factor allelic imbalance. The 95 and 99% CI
on the left are valid for any allelic constellation occurring in a given EUC
(EuroChimerism) marker, and are applicable if the monitoring of chimerism
in a transplant recipient is performed by a single STR (short tandem repeat)
marker. In instances in which a patient is monitored by two or more
different STR markers, the CI values on the right, which account for the
variation between different marker constellations, need to be applied.
Measured values (m) in consecutive patient samples which lie within
the indicated CI can be regarded as intrinsic variability of the method.
Conversely, consecutive values outside the CI reliably reflect actual
changes in the level of chimerism.
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implementing arithmetic formulas accounting for different allelic
constellations (Table 4).
Interpretation of chimerism levels
Changes in the level of chimerism can be interpreted as actual
increases or decreases, if the measured values of consecutive
samples are not within the intrinsic variability of the assay. Hence,
calculation of pointwise two-sided 95 and 99% confidence
intervals (Table 7) was performed for the assessment of individual
recipient/donor cell proportions, in order to provide a basis for
reliable quantitative analysis and monitoring of chimerism. The
EUC consortium has defined differences between subsequent
measurements as real changes in the level of chimerism if the
values were outside the 95% or more preferably the 99%
confidence intervals.
DISCUSSION
In this report, we present the results of the EuroChimerism
Concerted Action, which aimed at the establishment of a
standardized, European-harmonized approach to the detection
and monitoring of recipient/donor chimerism after allogeneic
stem cell transplantation. The availability of an assay optimized for
chimerism analysis in the European population should help
overcome the disadvantages resulting from the great hetero-
geneity of tests currently used for posttransplant monitoring.
Currently, nucleic acid amplification procedures based on in-house
assays or commercial kits for multiplex analysis of microsatellite
(STR) loci designed for forensic purposes are commonly being
used. The latter certainly provide a potentially useful option for
standardized analysis of chimerism, and the EUC consortium has
evaluated the adequacy of a commercial multiplex kit comprising
16 microsatellite markers (PowerPlex 16, Promega) for this
purpose. However, the requirements for the eligibility of micro-
satellite markers for clinical testing of chimerism are far more
stringent than those for forensic analysis. The allelic constellations
eligible for application in chimerism testing require not only
clearly distinguishable allelic patterns of donor and recipient,
but also a number of additional features relevant for quantitative
analysis of allele ratios.18 Essential criteria for marker selection
established by the EUC consortium include adequate achievable
sensitivity and the presence of bidirectionally informative
recipient and donor alleles unaffected by stutter peak formation
as a prerequisite for accurate quantitative analysis.
As specified below, our aim was the availability of at least two
alternative, informative markers eligible for quantitative monitor-
ing of chimerism according to the quality standards of the EUC
consortium in any donor/recipient constellation, which may be a
particular challenge in the related transplant setting. With regard
to the presence of multiple informative markers, testing of the
forensic multiplex kit in a large series of donor/recipient pairs
revealed suboptimal results, thus emphasizing the need for a
marker panel optimized for the specific requirements of chimer-
ism testing. The employment of multiplex reactions is instru-
mental in identifying markers suitable for subsequent monitoring
of chimerism, but our observations indicated that large multiplex
assays often do not provide the desired level of sensitivity
necessary for the assessment of lower levels of chimerism. This
limitation is attributable to the high degree of complexity of
multiplex reactions, and is apparently an inherent property of
assays targeting multiple STR markers in individual PCR reactions
(http://www.promega.com/applications; https://products.applied-
biosystems.com; http://www.biotype.de). We have therefore
established a panel of judiciously selected microsatellite markers
with optimized primer combinations permitting PCR amplification
under uniform conditions. The standardized PCR protocol facil-
itates both the performance of multiplex reactions for rapid
selection of informative markers, and singleplex reactions for
optimal sensitivity and quantitative analysis of recipient- and
donor-derived cells. The EUC panel was established on the basis of
a two-step selection process. First, a primary microsatellite panel
was complied by collecting the best-performing markers used at
the participating centers (Table 5). Subsequently, the pre-selected
markers were subjected to detailed analysis of allele frequencies
covering a broad spectrum of ethnic backgrounds in the European
population by testing a large series of related and unrelated
donor/recipient pairs in all centers of the consortium. For each
microsatellite marker tested, an important prerequisite for passing
this step of selection was the frequency of alleles complying with
the requirements for quantitative analysis of chimerism, as
defined by the consortium.18 On the basis of detailed investiga-
tion of allelic frequencies, the EUC panel was demonstrated to
provide multiple informative markers for the monitoring of
chimerism in any donor/recipient constellation, and was shown
to be superior in this regard to the commercial microsatellite
panel developed for forensic purposes. In contrast to this kit, the
higher degree of informativeness of the EUC panel can be
expected to provide a selection of markers optimally suited for
quantitative monitoring of chimerism according to the stringent
criteria established by our consortium18 in virtually any instance.
The general availability of multiple STR loci eligible for subsequent
chimerism testing offers the possibility to monitor a patient by
two or more different markers providing additional controls for
quantitative assessment of chimerism. The comparison of
independent measurements of chimerism or the calculation of
the mean of different measurements may be desirable in certain
situations to ensure the highest possible accuracy of quantitative
chimerism analysis.
Owing to the uniform conditions of amplification for all markers
included in the EUC panel, it is also conceivable to coamplify two
or three markers in one reaction without having to perform
extensive modifications of the assay. In this way, the level of
chimerism could be assessed as a median value of the markers
included, and the limited complexity of the reaction may be
expected to exert a minor effect on the DL of the assay.
The strength of the EUC panel is, however, only partly
attributable to the composition of markers and their high level
of informativeness. More importantly, the establishment of
singleplex assays with optimized primers and reaction conditions
for all markers of the EUC panel provided the basis for the
evaluation of essential parameters for standardized monitoring of
chimerism including sensitivity, reproducibility and accuracy, the
latter being a prerequisite for reliable assessment of quantitative
changes between consecutive samples. Singleplex reactions for
the analysis of individual markers of the EUC panel were shown to
have a DL for minor cell populations in the range of 0.8 --1.6% of in
most instances, and to display an excellent reproducibility in the
presence of adequate amounts of DNA template. In our study, PCR
reactions containing 10 ng of template, which corresponds to the
DNA content of about 1.500 diploid cells, were demonstrated to
provide the desired levels of reproducibility and sensitivity. The
use of lower DNA template amounts, as recommended in the
commercial multiplex kit tested, was associated with lower
achievable levels of sensitivity.
With regard to accuracy, the EUC panel is, to the best of our
knowledge, the only STR-PCR-based assay for chimerism testing
available in which the confidence intervals for quantitative
analysis have been established. The availability of this information
for all EUC singleplex PCR assays permits clear discrimination
between values representing actual changes in the level of
chimerism, and values that may indicate intrinsic variations
inherent in the methodology. This aspect is of particular relevance
for early assessment of rising recipient chimerism, which may
facilitate timely prediction of impending graft rejection or
relapse.1 -- 8
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Taken together, thorough investigation of the EUC panel in the
European population and detailed analysis of individual markers
demonstrated that the test system very adequately meets the
specific requirements of quantitative analysis of chimerism, and
provides an attractive option for diagnostic monitoring of patients
during the posttransplant period. The availability of a standardized
and European-harmonized methodology for chimerism testing is
an important step towards optimal surveillance and management
of allogeneic stem cell transplant recipients.
Concluding remarks
The EUC consortium has selected an industrial partner, Miltenyi
Biotec, to integrate the EUC marker panel (patent pending)
into a ready-to-use kit for chimerism testing. The availability
of a commercial kit produced under controlled industrial condi-
tions should promote wide implementation of a standardized
methodology for the detection (ChimerXplain) and quantitative
monitoring (ChimerXact) of chimerism in the clinical setting. Broad
use of the off-the-shelf kit could help eliminate the problems
of heterogeneity in the technical approaches used, and would
greatly facilitate the comparison of data and the exchange of
information between centers.
CONFLICT OF INTEREST
The EUC marker panel has been filed for patenting (A948/2006; PCT/AT2007/000266;
EP2 024 508-2009) and the IP rights were assigned to the EuroChimerism consortium
by an official document (Consortial Agreement). The IP rights were subsequently
obtained by the industrial partner of the EuroChimerism consortium, Milenyi Biotec,
Bergisch Gladbach, Germany. Revenues resulting from the recently launched kit based
on the EUC panel must be used for further activities of the EuroChimerism Consortium
in line with regulations specified in the consortial agreement.
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